Straits Times Index
3,187.66 +32.97 (+1.05%) S&P 500
5,039.20 +16.99 (+0.34%) Dow
37,932.20 +178.89 (+0.47%) Nasdaq
15,728.71 +45.33 (+0.29%) Bitcoin USD
63,394.20 +2,543.34 (+4.18%) CMC Crypto 200
885.54 0.00 (0.00%)
PMV Pharmaceuticals, Inc. (PMVP)
- GlobeNewswire
PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors
Rezatapopt is a first-in-class precision oncology investigational therapy for patients with advanced solid tumors with a TP53 Y220C mutation and KRAS wild-type (WT)First patient dosed in Phase 2 portion of the PYNNACLE trial which will assess rezatapopt as monotherapy in patients with TP53 Y220C and KRAS WT advanced solid tumors PRINCETON, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of sm
- GlobeNewswire
PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women’s Cancer
Phase 1 analysis from the PYNNACLE Phase 1/2 study showed promising efficacy of rezatapopt (PC14586) in heavily pre-treated patients with advanced ovarian cancer harboring a TP53 Y220C mutation featured in a late-breaking oral presentation at 2024 SGO Annual MeetingOf the 15 patients in the efficacy evaluable population, seven patients achieved a confirmed partial response with a seven-month median duration of response and a favorable safety profileRezatapopt is a first-in-class precision oncolo
- GuruFocus.com
PMV Pharmaceuticals Inc (PMVP) Reports Full Year 2023 Financial Results
Strategic Focus on Rezatapopt Advances as Company Extends Cash Runway
